// App-Quantinova.ai

OT1-02-01 : Pilot study of prognostic utility of circulating tumor cells (CTCs) assessed by AdnaGen technology and clinical outcome of patients with stage III breast cancer who completed locoregional and systemic treatment

Researchers

Presenter

  • Alvarez RH

Principal Investigators

  • Gao H

  • Ensor JE

  • Gomez HL

  • Ruiz-Garcia EB

  • Arce C

  • Sun H

  • Willey JS

  • Ueno NT

  • Valero V

  • Reuben JM

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Instituto Nacional de Cancerologia - INCAN, Mexico City, Mexico

  • Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru

Locations

  • United States

  • Mexico

  • Peru

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Skin carcinoma

  • Melanoma

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Cluster of Differentiation 44

  • Epithelial Cell Adhesion Molecule

  • Snail Family Transcriptional Repressor 1

  • Twist-related protein 1

  • Zinc finger E-box binding homeobox 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved